Regeneron: Buy Rating Supported by Eylea Stability and Pipeline Potential

In a report released on October 24, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron, with a price target of $785.00.

Salveen Richter’s rating is based on several key factors influencing Regeneron’s performance. The company’s shares have shown signs of recovery despite underperforming compared to the broader biotech index, largely due to the stabilization of earnings revisions related to Eylea and drug pricing dynamics. Investors perceive Regeneron’s stock as fairly valued, excluding its pipeline, and meeting expectations for the Eylea franchise is crucial for maintaining positive momentum.
Additionally, optimism surrounds the potential revenue growth following anticipated label enhancements for Eylea HD, with expectations of significant year-over-year growth. Regeneron’s focus on its internal pipeline, including the promising fi anlimab and other novel ophthalmology targets, positions the company for future revenue expansion. The management’s strategic priorities and potential drug pricing agreements further contribute to the positive outlook, supporting the Buy rating.

In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a $781.00 price target.